Aurobindo Pharma Limited vs Lupin Limited
A side-by-side comparison of Aurobindo Pharma Limited (AUROPHARMA) and Lupin Limited (LUPIN) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Lupin Limited leads AUROPHARMA vs LUPIN on 12 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation13
- Profitability04
- Growth02
- Size & financial health13
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
LUPIN takes 3/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
LUPIN takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
LUPIN takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
LUPIN takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- − ["Stock is trading at 2.52 times its book value", "The company has delivered a poor sales growth of 6.32% over past five years.", "Company has a low return on equity of 10.8% over last 3 years.", "Company might be capitalizing the interest cost"]
- + ["Company has delivered good profit growth of 37.0% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 17.1%", "Company's working capital requirements have reduced from 46.4 days to 28.0 days"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.